Get the latest delivered to your inbox
Privacy Policy

Now Reading

William Haseltine Joins OneWorld Health Board of Directors

William Haseltine Joins OneWorld Health Board of Directors

Published 12-16-04

Submitted by Institute for OneWorld Health

San Francisco, Calif. - The Institute for OneWorld Health, the first nonprofit pharmaceutical company in the U.S., today announced William A. Haseltine, Ph.D., has joined the Board of Directors. Recognized world-wide for his work on projects to facilitate better understanding of diseases such as HIV/AIDS and cancer, he is the founder of Human Genome Sciences, Inc. and served as Chairman and Chief Executive Officer from 1993 to Oct. 2004.

"We are honored to have such an accomplished individual who combines science and business in humanitarian pursuits," stated Victoria Hale, Ph.D., founder and CEO of OneWorld Health. "His scientific background is unequaled, and we commend his passion for social justice. He has translated his background, experience and interests into action to benefit humanity."

In the early 1980s, Dr. Haseltine conducted some of the first research on AIDS, and lobbied and raised funds for a disease many did not want to associate with at that time. He has demonstrated a commitment to social responsibility throughout his career, including his recent work in public service for organizations dedicated to a variety of issues ranging from world economic growth to technology and public policy to creating a national health museum in Washington, D.C.

"OneWorld Health has created a business model that is enabling some of the world's poorest people to receive new medical treatment that most of us in developed countries take for granted," said Dr. Haseltine. "I have seen the potential of modern medicine, and I am excited to be a part of this movement to deliver affordable treatments globally."

Dr. Haseltine received his undergraduate degree in physical chemistry at the University of California at Berkeley, followed by his Ph.D. from Harvard University in biophysics and a postdoctoral fellowship at Massachusetts Institute of Technology Center for Cancer Research. Following his education, he was employed as a faculty member at Harvard Medical School at Harvard School of Public Health for nearly 20 years. He currently serves on several editorial boards and has published more than 200 original reports, 71 books and monographs, and has edited seven publications. He also holds more than 50 patents issued by the U.S. Patent and Trademark Office. Dr. Haseltine serves on numerous boards, think tanks and international organizations. He is also a member of several organizations devoted to improving international relations. Some of his current work includes:

  • Executive Committee, Board of Trustees, The Brookings Institution
  • Member, Global Business Council on AIDS/HIV
  • Founder and Trustee of the Society for Tissue Engineering and Regenerative Medicine
The Institute for OneWorld Health, the first U.S. nonprofit pharmaceutical company develops new, affordable medicines for infectious diseases that disproportionately affect people in the developing world. OneWorld Health applies its entrepreneurial business model with a staff of experienced pharmaceutical scientists who identifies promising leads and drives development from pre-clinical studies to clinical trials through regulatory approval. The Institute for OneWorld Health, headquartered in San Francisco, Calif., is a tax-exempt 501(c) (3) U.S. corporation (www.oneworldhealth.org).

Institute for OneWorld Health

Institute for OneWorld Health

More from Institute for OneWorld Health

Join today and get the latest delivered to your inbox